{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T21:22:37Z","timestamp":1779916957719,"version":"3.53.1"},"reference-count":25,"publisher":"The Endocrine Society","issue":"5","license":[{"start":{"date-parts":[[2024,3,29]],"date-time":"2024-03-29T00:00:00Z","timestamp":1711670400000},"content-version":"vor","delay-in-days":17,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,3,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Context<\/jats:title>\n                  <jats:p>Continuous subcutaneous infusion of recombinant parathyroid hormone (rhPTH) through a pump has been proposed as a therapeutic alternative for patients with chronic hypoparathyroidism who remain symptomatic or hypercalciuric on conventional treatment (calcium and active vitamin D) or daily injections of rhPTH(1-84) or rhPTH(1-34). However, the real-world evidence of the outcome of this novel therapy is limited.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Case Descriptions<\/jats:title>\n                  <jats:p>We report the clinical and biochemical outcomes of 12 adults with hypoparathyroidism (11 women, age 30-70 years, and 1 man, age 30 years) from 3 different clinical sites in the United States who were transitioned from conventional therapy to daily injections of rhPTH(1-84) or rhPTH(1-34) and then switched to continuous administration of rhPTH(1-84)\/rhPTH(1-34) via pump therapy. In most patients, mean serum calcium concentrations increased while on PTH pump therapy compared with both conventional therapy (in 11 patients) and single\/multiple daily rhPTH injections (in 8 patients). Despite this, 10 patients had lower median 24-hour urinary calcium levels while on PTH pump therapy compared with prior therapy (mean \u00b1 SD difference: \u2212130 \u00b1 222\u2005mg\/24\u2005hours). All patients reported a qualitative decrease in hypocalcemic symptoms while receiving pump therapy. Three patients had pod failure at least once, and 1 patient developed an infusion site reaction.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>In this case series of 12 patients with chronic hypoparathyroidism treated with rhPTH(1-84)\/rhPTH(1-34) administered via a pump, improvement in clinical and biochemical parameters were observed in the majority of the patients. Our observations indicate benefits of pump administration of rhPTH that warrant further investigation.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1210\/jendso\/bvae053","type":"journal-article","created":{"date-parts":[[2024,3,29]],"date-time":"2024-03-29T08:09:25Z","timestamp":1711699765000},"source":"Crossref","is-referenced-by-count":8,"title":["Continuous Subcutaneous Delivery of rhPTH(1-84) and rhPTH(1-34) by Pump in Adults With Hypoparathyroidism"],"prefix":"10.1210","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6501-6180","authenticated-orcid":false,"given":"Nipith","family":"Charoenngam","sequence":"first","affiliation":[{"name":"Endocrine Unit, Massachusetts General Hospital, Harvard Medical School , Boston, MA 02114 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Bove-Fenderson","sequence":"additional","affiliation":[{"name":"Endocrine Unit, Massachusetts General Hospital, Harvard Medical School , Boston, MA 02114 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Wong","sequence":"additional","affiliation":[{"name":"Sutter Health , Sacramento, CA 95816 , USA"},{"name":"Baylor Scott & White Dallas Diagnostic Association , Garland, TX 75044 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3042-5336","authenticated-orcid":false,"given":"Natalie E","family":"Cusano","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Endocrinology, Lenox Hill Hospital , New York, NY 10022 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0867-9778","authenticated-orcid":false,"given":"Michael","family":"Mannstadt","sequence":"additional","affiliation":[{"name":"Endocrine Unit, Massachusetts General Hospital, Harvard Medical School , Boston, MA 02114 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2024,3,29]]},"reference":[{"issue":"1","key":"2024040110522110600_bvae053-B1","doi-asserted-by":"crossref","first-page":"17055","DOI":"10.1038\/nrdp.2017.55","article-title":"Hypoparathyroidism","volume":"3","author":"Mannstadt","year":"2017","journal-title":"Nat Rev Dis Primers"},{"issue":"6","key":"2024040110522110600_bvae053-B2","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1210\/jc.2015-3908","article-title":"Epidemiology and diagnosis of hypoparathyroidism","volume":"101","author":"Clarke","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2024040110522110600_bvae053-B3","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1210\/jc.2015-3909","article-title":"Presentation of hypoparathyroidism: etiologies and clinical features","volume":"101","author":"Shoback","year":"2016","journal-title":"J Clin Endocrinol Metabol"},{"issue":"12","key":"2024040110522110600_bvae053-B4","doi-asserted-by":"crossref","first-page":"2568","DOI":"10.1002\/jbmr.4691","article-title":"Evaluation and management of hypoparathyroidism summary statement and guidelines from the second international workshop","volume":"37","author":"Khan","year":"2022","journal-title":"J Bone Miner Res"},{"issue":"6","key":"2024040110522110600_bvae053-B5","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1210\/jc.2015-3907","article-title":"Management of hypoparathyroidism: summary statement and guidelines","volume":"101","author":"Brandi","year":"2016","journal-title":"J Clin Endocrinol Metabol"},{"key":"2024040110522110600_bvae053-B6","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1159\/000491047","article-title":"A new era for chronic management of hypoparathyroidism: parathyroid hormone peptides","volume":"51","author":"Marcucci","year":"2019","journal-title":"Front Horm Res"},{"issue":"10","key":"2024040110522110600_bvae053-B7","doi-asserted-by":"crossref","first-page":"R229","DOI":"10.1530\/EC-20-0366","article-title":"Challenges in the management of chronic hypoparathyroidism","volume":"9","author":"Zavatta","year":"2020","journal-title":"Endocr Connect"},{"issue":"6","key":"2024040110522110600_bvae053-B8","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s00223-010-9424-6","article-title":"Pharmacokinetics of teriparatide (rhPTH[1-34]) and calcium pharmacodynamics in postmenopausal women with osteoporosis","volume":"87","author":"Satterwhite","year":"2010","journal-title":"Calcif Tissue Int"},{"issue":"3","key":"2024040110522110600_bvae053-B9","doi-asserted-by":"crossref","first-page":"415","DOI":"10.4103\/ijem.IJEM_340_16","article-title":"Efficacy of teriparatide in patients with hypoparathyroidism: a prospective, open-label study","volume":"21","author":"Upreti","year":"2017","journal-title":"Indian J Endocrinol Metab"},{"issue":"1","key":"2024040110522110600_bvae053-B10","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s12020-020-02577-x","article-title":"Chronic hypoparathyroidism and treatment with teriparatide","volume":"72","author":"Marcucci","year":"2021","journal-title":"Endocrine"},{"issue":"1","key":"2024040110522110600_bvae053-B11","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1210\/jc.2017-01555","article-title":"PTH(1\u201334) for surgical hypoparathyroidism: a 2-year prospective, open-label investigation of efficacy and quality of life","volume":"103","author":"Palermo","year":"2018","journal-title":"J Clin Endocrinol Metabol"},{"issue":"9","key":"2024040110522110600_bvae053-B12","doi-asserted-by":"crossref","first-page":"3389","DOI":"10.1210\/jc.2007-2552","article-title":"Effects of once versus twice-daily parathyroid hormone 1-34 therapy in children with hypoparathyroidism","volume":"93","author":"Winer","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"2024040110522110600_bvae053-B13","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.jpeds.2018.08.010","article-title":"Long-Term parathyroid hormone 1-34 replacement therapy in children with hypoparathyroidism","volume":"203","author":"Winer","year":"2018","journal-title":"J Pediatr"},{"issue":"4","key":"2024040110522110600_bvae053-B14","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S2213-8587(13)70106-2","article-title":"Efficacy and safety of recombinant human parathyroid hormone (1\u201384) in hypoparathyroidism (REPLACE): a double-blind, placebo-controlled, randomised, phase 3 study","volume":"1","author":"Mannstadt","year":"2013","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"10","key":"2024040110522110600_bvae053-B15","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1002\/jbmr.470","article-title":"The effect of adding PTH(1\u201384) to conventional treatment of hypoparathyroidism: a randomized, placebo-controlled study","volume":"26","author":"Sikjaer","year":"2011","journal-title":"J Bone Miner Res"},{"issue":"5","key":"2024040110522110600_bvae053-B16","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/j.clinthera.2014.04.001","article-title":"Pharmacokinetics and pharmacodynamics of subcutaneous recombinant parathyroid hormone (1\u201384) in patients with hypoparathyroidism: an open-label, single-dose, phase I study","volume":"36","author":"Clarke","year":"2014","journal-title":"Clin Ther"},{"issue":"11","key":"2024040110522110600_bvae053-B17","doi-asserted-by":"crossref","first-page":"3308","DOI":"10.1210\/jc.2011-1359","article-title":"Long-Term results of continuous subcutaneous recombinant PTH (1-34) infusion in children with refractory hypoparathyroidism","volume":"96","author":"Linglart","year":"2011","journal-title":"J Clin Endocrinol Metabol"},{"key":"2024040110522110600_bvae053-B18","first-page":"EDM20","article-title":"Continuous rhPTH (1-34) treatment in chronic hypoparathyroidism","volume":"2020","author":"Fuss","year":"2020","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"key":"2024040110522110600_bvae053-B19","doi-asserted-by":"crossref","first-page":"e931739","DOI":"10.12659\/AJCR.931739","article-title":"Continuous teriparatide treatment in chronic hypoparathyroidism: a case report","volume":"22","author":"Saraiva","year":"2021","journal-title":"Am J Case Rep"},{"issue":"5","key":"2024040110522110600_bvae053-B20","doi-asserted-by":"crossref","first-page":"bvac031","DOI":"10.1210\/jendso\/bvac031","article-title":"Subcutaneous infusion of rhPTH(1-34) during pregnancy and nursing in a woman with autosomal dominant hypoparathyroidism 1","volume":"6","author":"Shulman","year":"2022","journal-title":"J Endocr Soc"},{"issue":"2","key":"2024040110522110600_bvae053-B21","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1056\/NEJMc2034981","article-title":"PTH infusion for seizures in autosomal dominant hypocalcemia type 1","volume":"385","author":"Sastre","year":"2021","journal-title":"N Engl J Med"},{"issue":"2","key":"2024040110522110600_bvae053-B22","first-page":"391","article-title":"Synthetic human parathyroid hormone 1-34 replacement therapy: a randomized crossover trial comparing pump versus injections in the treatment of chronic hypoparathyroidism","volume":"97","author":"Winer","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2024040110522110600_bvae053-B23","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.jpeds.2014.04.060","article-title":"Effects of pump versus twice-daily injection delivery of synthetic parathyroid hormone 1-34 in children with severe congenital hypoparathyroidism","volume":"165","author":"Winer","year":"2014","journal-title":"J Pediatr"},{"key":"2024040110522110600_bvae053-B24"},{"issue":"1","key":"2024040110522110600_bvae053-B25","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1152\/physrev.2001.81.1.51","article-title":"Magnesium transport in the renal distal convoluted tubule","volume":"81","author":"Dai","year":"2001","journal-title":"Physiol Rev"}],"container-title":["Journal of the Endocrine Society"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jes\/advance-article-pdf\/doi\/10.1210\/jendso\/bvae053\/57117162\/bvae053.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jes\/article-pdf\/8\/5\/bvae053\/57131359\/bvae053.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jes\/article-pdf\/8\/5\/bvae053\/57131359\/bvae053.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T10:53:00Z","timestamp":1711968780000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jes\/article\/doi\/10.1210\/jendso\/bvae053\/7637247"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,12]]},"references-count":25,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,3,12]]}},"URL":"https:\/\/doi.org\/10.1210\/jendso\/bvae053","relation":{},"ISSN":["2472-1972"],"issn-type":[{"value":"2472-1972","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,5]]},"published":{"date-parts":[[2024,3,12]]},"article-number":"bvae053"}}